Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Candel Therapeutics Inc. Common Stock
CADL | US
4.99
USD0.18
3.74%
CADL | US
Loading StockChartView...
About Candel Therapeutics Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
25/03/2026
Close
4.99
Open
4.92
High
5.13
Low
4.88
Candel Therapeutics Inc. a clinical stage biopharmaceutical company engages in the development immunotherapies for the cancer patients. It develops CAN-2409 which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110 which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the"enLIGHTEN Discovery Platform a systematic iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene Inc. and changed its name to Candel Therapeutics Inc. in November 2020. Candel Therapeutics Inc. was incorporated in 2003 and is based in Needham Massachusetts."
View LessCADL | US
Risk
49.2
Sharpe
-0.65
Luna's Score
42/100
Recommendation
Sell
Luna says (CADL | US)
What's Working
Low Debt to Equity (< 0.25)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
60.6%1 month
49.2%3 months
63.8%6 months
68.8%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
27.77
Debt to equity
-1.86
Debt to assets
0.70
Ent. to EBITDA
-0.01
Ent. to rev.
821.98
PEG
-
Other Fundamentals
EBITDA
-34.66M
MarketCap
160.10M
MarketCap(USD)
160.10M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-480.68
Short ratio
5.13
Short perc.
7.19
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.62
Range1M
0.92
Range3M
2.00
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.85
Price X volume
6.00M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.01 | 0.53 | Cheaper |
| Ent. to Revenue | 821.98 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 27.77 | 15.55 | Expensive |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 63.78 | 72.80 | Par |
| Debt to Equity | -1.86 | -1.23 | Cheaper |
| Debt to Assets | 0.70 | 0.25 | Expensive |
| Market Cap | 160.10M | 3.66B | Emerging |
